FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
ATLANTA, Oct. 25, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 1, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, November 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, November 2nd, 2017 9:00 AM ET
Conference dial-in: 877.269.7756
International dial-in: 201.689.7817
Conference Call Name: Alimera Sciences' Third Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early and late stage diseases. For more information, please visit www.alimerasciences.com.
Contact
CG CAPITAL
Rich Cockrell
877.889.1972
[email protected]
